Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D-2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas
Autore:
de Herder, WW; Reijs, AEM; de Swart, J; Kaandorp, Y; Lamberts, SWJ; Krenning, EP; Kwekkeboom, DJ;
Indirizzi:
Univ Rotterdam Hosp, Dept Internal Med 3, NL-3015 GD Rotterdam, Netherlands Univ Rotterdam Hosp Rotterdam Netherlands NL-3015 GD terdam, Netherlands Univ Rotterdam Hosp, Dept Nucl Med, Rotterdam, Netherlands Univ Rotterdam Hosp Rotterdam Netherlands l Med, Rotterdam, Netherlands
Titolo Testata:
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
fascicolo: 1, volume: 26, anno: 1999,
pagine: 46 - 50
SICI:
0340-6997(199901)26:1<46:COIEAI>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN BRAIN; I-125 EPIDEPRIDE; ADENOMAS; BINDING; SPECT; VISUALIZATION; IODINE-123-EPIDEPRIDE; BROMOCRIPTINE; PROLACTINOMAS; RADIOLIGAND;
Keywords:
pituitary; single-photon emission tomography; dopamine receptors; iodine-123 epidepride; iodine-123 IBZM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: de Herder, WW UnivRotterdam, Hosp, Dept Internal Med 3, Dr Molewaterplein 40, NL-3015 GD Univ Rotterdam Hosp Dr Molewaterplein 40 Rotterdam Netherlands NL-3015 GD
Citazione:
W.W. de Herder et al., "Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D-2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas", EUR J NUCL, 26(1), 1999, pp. 46-50

Abstract

We compared pituitary iodine-123 epidepride single-photon emission tomography (SPET) and I-123-IBZM SPET for the in vivo imaging of dopamine D-2 receptors in 15 patients with clinically non-functioning pituitary adenomas. Four patients with dopamine agonist-sensitive macroprolactinomas were studiedas positive controls. The uptake of radioactivity in the pituitary was established using a visual scoring system and an uptake index calculated by dividing the average count rates in the pituitary area by the average count rates in the cerebellum. All four macroprolactinomas showed specific bindingof I-123-epidepride, but only one showed specific binding of I-123-IBZM. Specific binding of I-123-epidepride was demonstrated in 9 of the 15 clinically nonfunctioning pituitary adenomas (60%), but specific binding of I-123-IBZM was shown in only 6 of these 15 cases (40%). The uptake of I-123-epidepride in the pituitary region was consistently higher than that of I-123-IBZM. None of the patients who showed absence of uptake of I-123-epidepride in the pituitary area showed uptake of I-123-IBZM in this area. In conclusion: I-123-epidepride SPET is superior to I-123-IBZM SPET for the visualization of dopamine receptor-positive pituitary adenomas. Therefore, I-123-epidepride should replace I-123-IBZM for future D-2 receptor SPET studies of pituitary adenomas. I-123-epidepride SPET potentially might serve to predict the response of clinically non-functioning pituitary adenomas to dopamine agonist therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/11/19 alle ore 03:38:56